Key Takeaways
- Maze Therapeutics reported promising phase 2 results for MZE829, an APOL1 inhibitor, showing a 35.6% reduction in protein levels in urine.
- Despite favorable data, Maze’s stock dropped 38% post-announcement, highlighting investor concerns over results in non-FSGS patients.
- The trial continues to enroll participants, and plans for a pivotal phase 3 trial are underway, targeting APOL1-mediated kidney disease.
Latest Developments in APOL1 Inhibitor MZE829
Maze Therapeutics has announced encouraging top-line phase 2 data for its lead candidate MZE829, an oral APOL1 inhibitor aimed at treating APOL1-mediated kidney disease (AMKD). The results showed an average 35.6% decrease in excess protein levels in the urine of 12 patients following 12 weeks of treatment, surpassing the 30% threshold that analysts had set as significant. Mizuho analysts suggest MZE829 has the potential to become a market leader in this treatment area.
While analysts view these findings positively, investor sentiment was notably negative. Following the announcement, Maze’s stock plummeted approximately 38%, dropping to around $30 per share by mid-morning. This market reaction highlights concerns regarding the treatment’s effectiveness in patients without focal segmental glomerulosclerosis (FSGS), a subtype of AMKD.
The primary aim of the open-label phase 2 Horizon trial is to evaluate safety, which preliminary results suggest is satisfactory, with no serious treatment-related adverse events. Minor side effects reported include headaches and diarrhea, although one patient discontinued due to nausea.
Maze is committed to advancing its research, planning to enter MZE829 into a pivotal trial while continuing to enroll participants in the Horizon study. The trial population consists of both diabetic and non-diabetic patients, although those with diabetes exhibited lower protein reductions.
Maze CEO Jason Columa emphasized the significance of these findings, stating this is the first clinical data to indicate a response in diabetic patients. Clarifying the study’s impact, Chief Medical Officer Harold Bernstein noted that the captured data will refine future patient selection for the phase 3 trial.
The trial results have sparked comparisons with Vertex Pharmaceuticals’ APOL1 inhibitor, inaxaplin, which previously demonstrated a 43% reduction in protein levels in a subset of AMKD patients with FSGS. Notably, MZE829 showed a 62% reduction among four similar participants, indicating competitiveness. Vertex is also conducting a larger phase 2/3 trial for inaxaplin in AMKD, with results expected later this year.
Despite Mizuho’s acknowledgment of MZE829’s solid dataset, they interpreted the stock’s drop as Wall Street’s reaction to the data surrounding non-FSGS patients. Analysts noted that this could be an overreaction, asserting that the different patient populations render direct comparisons less meaningful.
Analysts from Leerink Partners echoed this sentiment, cautioning against overinterpretation of the data. They suggested that although comparisons with other treatments are valid, the differing populations should be taken into account. The consensus remains that MZE829 has presented a convincing dataset, outpacing initial expectations and demonstrating a competitive edge in the evolving treatment landscape for kidney disease.
The content above is a summary. For more details, see the source article.